Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

June 20, 2022

Primary Completion Date

May 30, 2024

Study Completion Date

October 15, 2024

Conditions
HypercholesterolemiaAtherosclerotic Ischemic Disease
Interventions
BIOLOGICAL

lerodalcibep

300 mg

DRUG

Inclisiran

284 mg

Trial Locations (7)

424

The Lipid Clinic (Oslo University Hospital), Oslo

13385

Hopitaux de Marseille, Marseille

44093

CHU de Nantes - Hôpital Nord Laennec, Nantes

50009

Hospital Universitario Miguel Servet, Zaragoza

69120

Universitätsklinikum Heidelberg - Medizinische Klinik, Heidelberg

PL14 3XA

Oak Tree Surgery and Pensilva Health Centre, Liskeard

OL6 6EW

Ashton Medical Group, Ashton-under-Lyne

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

LIB Therapeutics LLC

INDUSTRY